Life Sciences and Technology IPO and SPAC Overview Panel

Presented on February 9, 2021

Findley Gillespie, Partner, Life Sciences Practice
Jeremy Kuhlmann, Partner, Life Sciences Practice
Amanda Rose, Corporate Partner, Fenwick

2020 was another active year in the life sciences and technology markets, despite the impacts of COVID-19. View our panel with Moss Adams Partners Jeremy Kuhlmann and Findley Gillespie and Fenwick Corporate Partner Amanda Rose, as we recap 2020, look at 2021, and discuss considerations for companies contemplating public exits via initial public offerings (IPOs) or special purpose acquisition companies (SPACs).

Contact Us with Questions

Enter security code:
 Security code